Project Grant R01CA299139
Award Date 6/1/26
Completion Date 5/31/29
Dollars Obligated $772K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $661,721 to the University of California, San Diego under the Cancer Biology Research program (CFDA 93.396) beginning April 1, 2026, through March 31, 2031. This project grant supports systematic functional mapping and mechanistic interrogation of intrinsically disordered regions (IDRs) in oncogenic proteins across a five-year research period. The research deliverables include the development and application of novel...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $650,597 Project Grant to the University of California, San Diego under the Cancer Treatment Research program (CFDA 93.395) for the period April 1, 2026 through March 31, 2031. This research project investigates the role of B-cells in durable complete responses to checkpoint blockade immunotherapy (CBI) in head and neck squamous cell carcinoma (HNSCC). While response rates to CBI in HNSCC remain generally low,...
- Federal Grant Award Summary The National Cancer Institute awarded University of California, San Diego a $699,929 Project Grant on June 20, 2025, under the Cancer Treatment Research program (CFDA 93.395) to enhance immunotherapy response in human papillomavirus negative head and neck squamous cell carcinoma (HPV-HNSCC). The project, which extends through May 31, 2030, focuses on improving dendritic cell (DC) migration to draining sentinel lymph nodes to enhance the efficacy of programmed...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for research activities spanning August 8, 2025 through July 31, 2027. This award funds a discovery-focused research initiative investigating functional immune niches within the tumor microenvironment (TME) that support effective cancer immunotherapy responses. The primary deliverable...
- Federal Grant Award Summary The University of California, San Diego received a $694,643 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective May 7, 2026, through April 30, 2031. The project, titled "Targeting the Hippo-YAP/TEAD Signaling Network in Head and Neck Cancer," focuses on developing improved treatment approaches for head and neck squamous cell carcinoma (HNSCC). The research aims to advance beyond...
- Federal Grant Award Summary The University of California, San Diego received a $420,505 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), with an award period from April 1, 2026 through March 31, 2028. The grant supports research into plant virus-based adjuvants as therapeutic agents, specifically investigating Cowpea Mosaic Virus (CPMV) as a potent immunomodulator for infectious disease and cancer vaccines. The research focuses on...
- Federal Grant Award Summary The University of California, San Diego received a $411,206 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to develop small molecule inhibitors targeting the proton-sensing receptor GPR68 for pancreatic ductal adenocarcinoma (PDAC) therapy. The research addresses the critical need for novel treatment approaches, as PDAC accounts for approximately 90% of pancreatic cancers and carries only an 8% five-year...
- Federal Grant Award Summary The National Cancer Institute awarded the University of California, Irvine a $648,626 Project Grant on April 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate mechanisms of immunosuppression triggered by checkpoint blockade immunotherapy (CBI). The research addresses a critical gap in understanding why PD-1 inhibitor monotherapy and dual checkpoint inhibitor combinations fail in the majority of cancer patients. The study will examine...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $677,787 to The Regents of the University of California, San Francisco on August 26, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award supports a five-year research initiative (through July 31, 2030) investigating AIRE-expressing tumor-associated macrophages (AIRE+ TAMs) as novel mediators of tumor immune evasion. The research aims to characterize the molecular and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $663,340 Project Grant to the University of California, Berkeley under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on regulatory T cell-mediated suppression of tumor elimination. The award, made on August 27, 2025 with completion targeted for July 31, 2030, will fund investigations into how the local ablation of intra-tumoral regulatory T cells (IT-Tregs) mobilizes natural killer...